Pacific Beach BioSciences Licenses Novel Fluoroquinolone From Korean Firm Dong Wha
This article was originally published in PharmAsia News
Executive Summary
Pacific Beach BioSciences, a San Diego start-up, and Dong Wha Pharmaceutical have signed a development and commercialization deal for zabofloxacin, a novel fluoroquinolone antibiotic discovered by the Korean pharma, the companies announced Aug. 10
You may also be interested in...
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required.)